Primary results of the exploratory CORALLEEN phase 2 trial showed that neoadjuvant ribociclib and letrozole in high-risk Luminal B breast cancer achieved similar rates of risk of recurrence (ROR)-low disease at surgery as multi-agent chemotherapy. These findings suggest that a chemotherapy-free treatment strategy based on cyclin-dependent kinase (CDK)4/6 inhibition in these patients is worth exploring in future neo(adjuvant) trials.
Although different approaches for treatment de-escalation are being investigated, the current ongoing phase 3 adjuvant trials with CDK4/6 inhibitors are not addressing the question of whether these drugs can replace multi-agent chemotherapy in high-risk early breast cancer. In the CORALLEEN phase 2 trial, the efficacy of ribociclib plus endocrine therapy as neoadjuvant treatment in patients with high-risk Luminal B disease is being assessed . The study was designed as an open-label, parallel, multicentre, two-arm, randomised explora...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Breast cancer incidence decreased by oestrogen alone but increased by adding progestin Next Article
Positive effects of adding pertuzumab to trastuzumab + chemotherapy in operable HER2 breast cancer »
Table of Contents: SABCS 2019
Screening, Detection, and Diagnosis
Phase 2 Trial Update
Phase 3 Trial Update
Long-Term Study Results
Triple-Negative Breast Cancer
HER2-Positive Breast Cancer
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.